Anti-Aging Therapy: Separating the Wheat from the Chaff

 

Few terms in contemporary medicine carry more weight and less precision than "anti-aging." It appears on laboratory publications and lipstick packaging with equal confidence. It is invoked by Nobel Prize winners and infomercial hosts within the same news cycle. It promises everything and, when examined carefully, has so far delivered far less than its advocates claim. The source of this confusion is not difficult to locate. Anti-aging means genuinely different things to three genuinely different communities — science, medicine, and commerce — and these three communities have been talking past each other, and at the public, for more than two decades. Before any honest evaluation of anti-aging therapy is possible, the definitions must be separated, their evidence bases assessed independently, and their boundaries mapped with precision.

What Medicine Already Had

The oldest, most established, and most clinically practiced definition belongs to the medical community. In medicine, anti-aging has always meant the early detection, prevention, and treatment of age-related diseases. This is a legitimate and achievable clinical enterprise with a long, documented, and verifiable record. It is what physicians do every day — identifying cardiovascular risk before the first event, managing diabetes before its complications, treating arthritis before it immobilizes, screening for cancer before it spreads.

This definition is categorically different from intervening in the aging process itself, and medicine has never pretended otherwise. Preventing cardiovascular disease or managing type 2 diabetes may help a person live longer and better, but it does not slow the biological clock. It removes one obstacle from a landscape that contains many others. The person who survives their first cardiac event does not thereby escape the hierarchy of age-related pathology — they simply advance to the next level of it. This is not a limitation of the medical definition. It is an honest description of what medicine can offer, and why that honesty is its greatest strength. Its outcomes are measurable in individual patients within observable timeframes. Its failures are visible and correctable. Its successes do not require waiting for a full lifespan to confirm.

This definition was never in serious dispute inside clinical medicine. The confusion came from outside it.

What Science Cannot Agree On

Within the scientific community, no consensus definition of anti-aging has ever been established. At least three distinct camps have been fighting over meaning, legitimacy, and funding for decades — each claiming the same term for fundamentally different purposes.

The first camp — mainstream gerontologists — insists that anti-aging in science means exclusively intervening in the biological aging process itself: the underlying mechanisms of senescence that drive the accumulation of molecular and cellular damage over time. Representatives of this position include Leonard Hayflick, S. Jay Olshansky, and Bruce Carnes, who in 2002 published a formal Position Statement on Human Aging signed by 51 scientists explicitly stating that no currently available intervention had been proven to slow aging in humans, and warning the public against anti-aging claims. Their position remains scientifically unassailable: in 2026, after more than two decades of intensive research, it is still true that no intervention has been proven to slow the biological aging process in humans.

The second camp — translational biogerontologists — accepts a broader definition that includes preventative approaches to age-related disease as legitimate anti-aging medicine. Represented by researchers such as Valter Longo, Luigi Fontana, and the participants of the 2013 Erice conference on interventions to slow aging in humans, this group describes caloric restriction mimetics, rapamycin analogs, and similar interventions as anti-aging because they extend healthy lifespan in animal models, even in the absence of proven human longevity extension. Their position is clinically more useful but epistemologically less precise — it conflates promising preclinical evidence with established human benefit in ways that can mislead patients and regulators.

The third camp — longevity entrepreneurs embedded in science — operates with a definition that is openly expansive. Represented most visibly by David Sinclair, Aubrey de Grey, and their associated institutions and companies, this group treats any intervention targeting a mechanism of aging as anti-aging medicine, and handles the distance between animal evidence and human clinical reality as a communication strategy rather than an epistemological boundary. When Sinclair writes that "aging is apparently reversible" in response to FDA clearance of a first-in-human eye injection trial, he is compressing cellular observation into organismal claim in a single sentence — a move that serves the narrative of his research program more honestly than it serves the patient trying to understand what the science actually shows.

Biogerontologist David Gems, writing in Experimental Gerontology in 2014, attempted to resolve this internal scientific division by proposing a more pragmatic definition: anti-aging treatment as any preventative approach to late-life pathology, based on his argument that aging is not a single upstream process but a complex disease syndrome of multiple pathologies in shifting rank order. This redefinition brought science closer to the medical community's practical orientation and was more honest than the standard model it replaced. However, it carries a significant conceptual problem that must be named directly. Equating aging with disease syndrome contradicts a well-documented clinical reality: a substantial proportion of people live through their entire lifespan without developing identifiable pathology, experiencing instead what medicine properly calls physiological aging — the natural, gradual progression of biological change that is entirely compatible with health, function, and coherent selfhood until very close to biological death. Aging and disease are not the same phenomenon. Disease is a deviation from the biological norm. Physiological aging is the norm itself. Conflating the two does not clarify the field — it imposes a pathological frame onto a natural process, feeding precisely the cultural devaluation of old age that the commercial anti-aging marketplace exploits. Furthermore, even within Gems' own framework, the deeper disagreement between the three scientific camps about what anti-aging science is ultimately trying to achieve remained entirely unresolved — and the question of what medicine owes the person who lives fully beyond the reach of prevention, whether in pathological or physiological aging, was left entirely unanswered.

What Commerce Did to Both

Beyond science, the commercial marketplace imposed a fourth definition entirely: anti-aging as a brand — a proven mechanism for selling products that range from rigorously studied interventions to outright fraud. This marketplace has so thoroughly colonized public understanding that it has damaged the credibility of legitimate science and legitimate medicine simultaneously. It cherry-picks supportive studies in areas where the evidence is still unsettled, assembles disconnected research results into misleading narratives, and sells the appearance of youth without biological foundation. As the Cambridge English Corpus documents directly, the anti-aging movement has contributed to "the social devaluation of the final stage of human life" — positioning aging itself as a failure and every aging person as someone losing a war they should be winning. This cultural damage is not incidental. It is the direct consequence of allowing a medical concept to be colonized by commercial interests without resistance.

What the Evidence Actually Shows

When the three scientific camps and the commercial marketplace are set aside, and the evidence is assessed on its own terms, the picture is consistent and sobering across two decades.

A 2002 analysis stated plainly that there was "no proven and available medical technology that slows or reverses aging in humans" and that there was no method short of waiting for people to die to accurately measure the effects of an alleged anti-aging therapy. A 2022 peer-reviewed PMC review reached the identical conclusion: "there is currently no proven way to slow the aging process in humans even slightly." Twenty years of intensive research, enormous investment, and accelerating public interest separate these two statements. Their content is the same.

The Measurement Problem No One Wants to Name

Underlying every claim of longevity extension is a methodological problem the field has consistently failed to confront directly: human longevity cannot be measured without observing a complete life. To demonstrate that a therapy has extended human lifespan requires a longitudinal study design, comparative controls observed across full lifespans, and rigorous accounting for every competing cause of death and functional decline. No trial currently designed comes close to meeting this standard. Without a comparable case against which to measure, the claim of longevity extension cannot even be properly formulated, let alone proven.

Furthermore, cellular reversibility of aging does not equal tissue reversibility, which does not equal organ reversibility, which does not equal human organismal longevity extension. Each step up that hierarchy introduces enormous additional complexity and requires independent evidence. Every rejuvenated cell is immediately recruited back into an organism that continues aging at every other level simultaneously. The organism is not a collection of locally younger cells. It is an orchestrated system whose properties emerge from the relationships between all levels together — and that system has never been shown to be reversible in a living human being.

Where Anti-Aging Therapy Actually Lives: Two Legitimate Domains

Once unsupported claims are set aside, what remains is genuinely valuable and maps precisely onto two distinct and defensible clinical domains — both of which belong to the honest medical definition that was always there.

The first domain is primary prevention within healthspan. This encompasses evidence-based behavioral, nutritional, and emerging pharmacological strategies that reduce the accumulation of age-related pathology before it reaches clinical threshold. Regular physical activity, nutritional quality, deliberate fasting, restorative sleep, stress regulation, and rich social engagement all have supporting evidence. Certain pharmacological candidates are under serious investigation. These strategies work with the biological program rather than claiming to override it — which is precisely why their evidence base is more durable than that of more dramatic interventions. They are the foundation that nature already encoded, refined by clinical science, and they represent the most powerful anti-aging tools currently available to any human being.

The second domain is secondary prevention within wellspan. When healthspan has already been lost — when the person is already living with heart failure, vision loss, joint failure, or cognitive decline — the question is no longer how to prevent disease. It is how to preserve the person within the disease: their identity, agency, connection, and capacity for meaningful participation in their own life. Cardiac pacemakers, joint replacements, cochlear implants, and emerging cellular rejuvenation therapies for optic neuropathies all operate in this domain. They do not slow aging. They restore lost function and keep the conscious self present and participatory within a biological life already fully engaged with its pathologies. This is wellspan medicine. Its goal is the compression of second mortality — the erasure of the conscious self before the biological death of the body — which remains the most prevalent and least addressed form of human suffering in late life.

The Three Borders That Must Be Respected

Any honest accounting of anti-aging therapy must observe three distinct and non-negotiable borders.

The first separates legitimate primary prevention — evidence-based strategies serving healthspan — from commercial products that sell the appearance of youth without biological foundation.

The second separates legitimate secondary prevention — restorative interventions serving wellspan — from the claim that such interventions constitute longevity extension. Restoring vision does not add years to life. It adds life to years. These are not the same claim, and conflating them misleads patients, misdirects research funding, and distorts public understanding of what medicine can and cannot currently achieve.

The third and most important border separates what current science has demonstrated from what it aspires to demonstrate. In 2026, anti-aging science has produced compelling theory, powerful animal models, and the first tentative steps into human trials of cellular rejuvenation. It has not produced proven human longevity extension. A critical distinction must be stated precisely here: cellular rejuvenation does not mean longevity increase. The first human trial of partial epigenetic reprogramming — ER-100, targeting retinal ganglion cells in optic neuropathies — is a Phase 1 safety study for a specific disease process. Its ceiling of demonstrated achievement, even under the most optimistic projections, is the safe restoration of function in specific cell populations within an anatomically isolated tissue. The eye was chosen precisely because it is immunologically shielded from the systemic regulatory architecture that governs the rest of the organism. Success there tells us almost nothing about what cellular reprogramming would do in tissues fully embedded in the aging organism's circulatory, immune, and neural systems. And even systemic cellular rejuvenation — undemonstrated in any human — would not automatically equal human longevity extension, because the organism is not a collection of locally younger cells. It is an orchestrated system whose properties emerge from relationships between all levels together. Cellular reversibility of aging, tissue restoration, organ recovery, and human organismal longevity are not the same claim at different scales. They are different levels of biological reality, each requiring independent evidence that does not yet exist.

That goal — human longevity extension — therefore remains a scientific marvel: an aspiration supported by elegant theory and compelling preclinical data, rather than a clinical reality supported by human evidence. Presenting aspiration as achievement is not science. It is the same marketing logic that has corrupted the anti-aging brand for two decades, dressed in laboratory language rather than cosmetic packaging. The costume is more credible. The logic is the same.

Returning to What Medicine Already Knew

The conclusion of this analysis is not a new discovery. It is a restoration. The medical community definition — early detection, prevention, and treatment of age-related diseases — was always the most honest, most verifiable, and most clinically useful definition available. It did not need to be invented. It needed to be defended against the scientific camps that tried to replace it with grander claims, and against the commercial marketplace that tried to exploit it for profit.

That defense now requires one essential extension that medicine has not yet formally made. The medical definition serves the person well while healthspan remains. But the majority of aging people are already beyond the reach of prevention. For them, medicine's obligation does not end — it transforms. The goal becomes preserving the person within the disease: their identity, agency, connection, and participation in their own life. This is wellspan. Together with the honest medical definition of anti-aging, it constitutes the complete and defensible map of what medicine can offer aging human beings today.

Everything outside that map — every claim that human aging has been reversed, that longevity has been measurably extended, that the biological clock has been reset in a living person — remains at this moment aspiration dressed as achievement. It may become real. The science is serious and the direction is right. But aspiration is not medicine. And the people who need medicine deserve the difference to be named clearly, defended consistently, and never traded away for the sake of a headline, a funding round, or a press release.

The wheat in this field is real, valuable, and worth every effort to protect. The chaff is not harmless — it consumes the trust, the resources, and the time that honest medicine needs to serve the people who are aging right now, today, in the only life they have.

You can learn more by reading our e-books or listening to our audiobooks on Google Play

Mykola Iabluchanskyi (Yabluchansky) together with Andriy Yabluchanskiy